Subscribe

Shitanshu Uppal

ATtend Trial: Atezolizumab + chemotherapy for advanced or recurrent endometrial cancer

Atezolizumab with chemotherapy improved progression-free survival in advanced or recurrent endometrial carcinoma, especially in dMMR tumors, though overall survival hasn't shown significant benefit yet. In the pMMR population, no significant PFS or OS benefit was observed; OS benefit is minimal.

Secondary Debulking Mini-Tutorial

Low-Grade Serous Ovarian Carcinoma

Relevant Study Summaries GOG 281: Trametinib in recurrent low-grade serous

MILO/ENGOT-ov11: Binimetinib in Recurrent Low-Grade Serous

In low-grade serous ovarian cancer, Binimetinib did not significantly improve PFS compared to standard of care chemotherapy.

Publications Update # 67

Human creativity and the need for connection, mini-tutorial on low-grade serous ovarian cancer, p53 on preoperative biopsy in endometrial cancer, final overall survival in SOC-1 trial

SOC-1

Surgery did not improve overall survival, but it showed a benefit in certain analyses. This supports the potential efficacy of secondary cytoreduction in specialized centers and for selected patients.

Platinum-Resistant Recurrent Ovarian Cancer

AURELIA Trial: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer

Adding bevacizumab to chemotherapy significantly improves PFS and ORR in patients with platinum-resistant recurrent ovarian cancer.

Platinum Sensitive Recurrent Ovarian Cancer

OCEANS Trial: Bevacizumab Maintenance in Platinum Sensitive Recurrence

- Adding bevacizumab to gemcitabine and carboplatin significantly improves PFS but no difference in OS in platinum-sensitive recurrence